Biotech | April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Supply increase to help meet growing global demand
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
BVX-0922 to target colorectal cancer under investigator-sponsored IND
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Co–Founder Sam Santhosh steps down as Chairman and Group CEO; will remain on Board of Directors. Co–founder Mahesh Pratapneni appointed Group CEO. Dr. Felix Olale appointed Chairman of the Board
This drive will expand access to quality diagnostics and help find the ‘missing millions’ – patients that are suffering from TB but not registered in the healthcare system
A staggering 65% of the TB cases in India are in the 15-45 age group
Christian brings a unique level of experience and expertise from a 20-year career at BASF across multiple territories and businesses
Subscribe To Our Newsletter & Stay Updated
